Carprofen

Overview

Carprofen (Rimadyl®, Carprieve®, Carprovet®, Norocarp®, Novox®, quellin®, Rovera®, Vetprofen®) is a propionic acid–derivative nonsteroidal anti-inflammatory drug (NSAID) used in dogs and, with caution, in cats for its analgesic and anti-inflammatory properties.

In dogs, carprofen is widely used for the management of osteoarthritis and for control of postoperative pain associated with soft tissue and orthopedic procedures. It is generally well tolerated, with a low reported incidence of serious adverse effects when used at recommended doses.

Mechanism of Action (MOA): Carprofen exerts analgesic, anti-inflammatory, and antipyretic effects primarily through inhibition of cyclooxygenase (COX) enzymes and subsequent reduction of prostaglandin synthesis. In dogs, it appears relatively COX-2 preferential at labeled doses, contributing to a lower incidence of COX-1–associated adverse effects such as gastrointestinal ulceration and platelet dysfunction compared with older nonselective NSAIDs.

Carprofen is highly protein bound and extensively metabolized in the liver. Because NSAIDs may affect renal perfusion and hepatic function, appropriate patient selection and monitoring are essential, particularly in geriatric animals or those with concurrent systemic disease.

Indications

Carprofen is indicated in dogs for the management of pain and inflammation associated with musculoskeletal disorders and surgical procedures. In cats, use is extra-label and limited to carefully selected short-term protocols.

• Osteoarthritis (dogs):
  Labeled for control of pain and inflammation associated with degenerative joint disease. Long-term administration may provide sustained clinical improvement when appropriately monitored.
• Postoperative pain (dogs):
  Indicated for control of pain associated with soft tissue and orthopedic surgeries. Preoperative administration may reduce inhalant anesthetic requirements.
• Prostatic carcinoma (dogs):
  May provide clinical benefit and has been associated with improved survival time in affected dogs.
• Postoperative analgesia (cats – extra-label):
  Used as a single perioperative dose for short-term pain control. Repeated dosing requires extreme caution due to increased risk of adverse effects.

Dosage (Reference)

Dog

In dogs, carprofen is FDA-approved for management of osteoarthritis pain and for control of postoperative pain. The total daily dose is 4.4 mg/kg and may be administered once daily or divided into two doses.

Cat

All carprofen use in cats in the United States is extra-label. Extreme caution is advised, particularly with repeated dosing, due to limited glucuronidation capacity and increased risk of renal and gastrointestinal adverse effects.

Warnings & Precautions

Carprofen is generally well tolerated in dogs when used at labeled doses; however, as with all NSAIDs, appropriate patient selection, baseline evaluation, and ongoing monitoring are essential to minimize the risk of serious adverse effects.

• Bleeding disorders (dogs):
  Contraindicated in dogs with bleeding disorders (e.g., Von Willebrand disease, thrombocytopenia) due to potential impairment of hemostasis.
• Previous NSAID reactions:
  Contraindicated in animals with a history of serious adverse reactions to carprofen or other propionic acid–class NSAIDs (e.g., ketoprofen, naproxen, ibuprofen).
• Geriatric or systemically ill patients:
  Use caution in geriatric animals and in those with chronic disease (e.g., inflammatory bowel disease, cardiovascular disease, renal or hepatic insufficiency, dehydration, hypoproteinemia).
• Renal perfusion risk:
  NSAIDs may reduce renal blood flow, particularly in hypotensive, dehydrated, or anesthetized patients. Consider perioperative IV fluids to reduce risk of renal injury.
• Hepatic monitoring:
  Rare idiosyncratic hepatotoxicity has been reported in dogs. Baseline and follow-up liver enzyme evaluation is recommended, especially during long-term therapy.
• Young dogs:
  Safety has not been established in dogs younger than 6 weeks of age.
• Bone healing (dogs):
  Prolonged administration (e.g., several months) has been shown to inhibit bone healing in experimental settings; use cautiously after orthopedic procedures requiring long-term healing.
• Cats – extreme caution:
  Cats have limited glucuronidation capacity, increasing the risk of drug accumulation and toxicity. Repeated dosing substantially increases the risk of renal and gastrointestinal adverse effects.
• Concurrent medications:
  Use caution in animals receiving corticosteroids or other nephrotoxic drugs due to increased risk of GI or renal complications.

Drug Interactions

As an NSAID, carprofen may interact with medications that affect gastrointestinal integrity, renal perfusion, platelet function, or protein binding. Concomitant therapy requires careful risk–benefit assessment and appropriate monitoring.

• Other NSAIDs (including aspirin):
  Concurrent use increases the risk of gastrointestinal ulceration and renal toxicity. Avoid combination. When switching from aspirin, a washout period of 3–10 days is recommended.
• Corticosteroids:
  Concomitant administration increases the risk of serious GI adverse effects (e.g., ulceration, perforation). Avoid concurrent use.
• ACE inhibitors (e.g., enalapril, benazepril):
  NSAIDs may reduce the antihypertensive and renal-protective effects of ACE inhibitors. Monitor renal function and blood pressure.
• Loop diuretics (e.g., furosemide):
  May reduce diuretic efficacy and increase the risk of renal insufficiency due to decreased renal perfusion.
• Cyclosporine and other nephrotoxic drugs:
  Increased risk of nephrotoxicity when used concurrently.
• Anticoagulants or antiplatelet drugs:
  Increased risk of bleeding due to additive effects on platelet function and GI mucosa.
• Highly protein-bound drugs (e.g., phenytoin, sulfonamides, valproic acid):
  Because carprofen is highly protein bound, it may displace other highly bound drugs, potentially increasing their serum concentrations.
• Digoxin:
  Carprofen may increase serum digoxin concentrations; monitor patients with cardiac disease closely.
• Methotrexate:
  NSAIDs may increase and prolong methotrexate plasma concentrations, increasing the risk of toxicity.
• Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants:
  Concurrent use may enhance antiplatelet effects and increase bleeding risk.
• Insulin or oral antidiabetic agents:
  NSAIDs may enhance hypoglycemic effects; monitor blood glucose as indicated.

Side Effects & Overdose

Side Effects

Carprofen is generally well tolerated in dogs at labeled doses. Most adverse effects are gastrointestinal and mild; however, serious hepatic or renal complications may occur rarely. Cats are more susceptible to adverse effects, particularly with repeated dosing.

• Gastrointestinal effects (most common):
  Vomiting, diarrhea, constipation, inappetence, and mild lethargy. Incidence in dogs is low (reported <2%), but risk increases with concurrent ulcerogenic drugs.
• Gastrointestinal ulceration or bleeding:
  May present as melena, hematemesis, anemia, or abdominal pain. Subclinical erosions may occur with chronic use.
• Hepatotoxicity (rare, dogs):
  Idiosyncratic hepatocellular injury has been reported (≈0.05% or less). Clinical signs may include anorexia, vomiting, jaundice, or elevated liver enzymes.
• Renal toxicity:
  Risk increases in dehydrated, hypotensive, or preexisting renal-compromised patients. May present as azotemia, polyuria, or polydipsia.
• Neurologic or behavioral changes:
  Ataxia, weakness, seizures, sedation, restlessness, or aggression have been reported rarely.
• Hematologic abnormalities:
  Immune-mediated hemolytic anemia, thrombocytopenia, epistaxis, or blood-loss anemia have been reported infrequently.
• Dermatologic or hypersensitivity reactions:
  Pruritus, facial swelling, erythema, urticaria, alopecia, or vasculitis may occur.
• Cats:
  Increased risk of renal adverse effects and gastrointestinal toxicity, particularly with repeated administration due to limited glucuronidation capacity.

Overdose

Carprofen overdose can result in dose-dependent gastrointestinal and renal toxicity. Clinical response may vary considerably between patients.

• Common overdose signs:
  Vomiting, diarrhea, anorexia, lethargy, melena, and elevated liver enzymes.
• Renal injury:
  Azotemia may develop at higher doses, particularly in cats, which have a lower threshold for renal toxicity.
• Hepatic injury:
  Elevated ALT or other liver enzymes may occur following acute or chronic overdose.
• Management:
  Early decontamination (emesis and/or activated charcoal) may be appropriate after recent ingestion. Provide GI protectants and IV fluid diuresis if renal compromise is suspected.
• Advanced therapy:
  Therapeutic plasma exchange or IV lipid emulsion therapy has been reported in severe cases.

Key Notes

Practical clinical considerations to optimize safe and effective use of carprofen in dogs and cats:

• Once-daily vs divided dosing (dogs):
  The total daily dose may be administered once daily or divided twice daily; some patients demonstrate improved tolerance with divided dosing.
• MAC-sparing effect:
  Preoperative administration may reduce inhalant anesthetic requirements during surgery.
• Tablet handling:
  Chewable and flavored tablets are palatable; store securely to prevent accidental ingestion.
• Breed considerations:
  Labrador Retrievers were overrepresented in early hepatopathy reports, but current evidence does not confirm breed predisposition; remain vigilant in all breeds.
• Chronic osteoarthritis management:
  Long-term NSAID therapy may significantly improve mobility and quality of life when integrated into a multimodal plan (e.g., weight management, rehabilitation).
• Thyroid testing interpretation (dogs):
  Carprofen may mildly lower total T4, free T4, and TSH concentrations; interpret thyroid panels cautiously in treated patients.
• Injection handling:
  Refrigerate injectable formulations as directed and observe storage limits once broached.
• Client communication:
  Emphasize early reporting of appetite changes or behavior changes, as early detection of adverse effects improves outcomes.